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Abstract
Eight oxytocin (OT) antagonists with general structure Mpa1Sar7Arg8, substituted at position 2 with conformationally constrained and
bulky amino acids, were synthesized and pharmacologically tested. Binding affinities and selectivities of compounds for OT, and vasopressin
receptor subtypes were investigated. In vitro effects of antagonists were evaluated via inhibition of OT-induced contractions of isolated
guinea-pig uterus. The abilities of OT antagonists to inhibit spontaneous contractility in 24 h postpartum rat uterus were investigated. These
peptides exhibited pseudoirreversible pharmacological properties, and comprise a novel group of OT antagonists for potential clinical use.
Their noncompetitive pharmacological nature can be of therapeutic benefit through a sustained effect on myometrium.
© 2002 Elsevier Science Inc. All rights reserved.
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1. Introduction
Although the average duration of gestation in women is
40 weeks, it is estimated that nearly 13 million babies are
born preterm worldwide each year. The considerable vari-
ability in the timing of childbirth poses particular problems
for both mother and baby: the shorter the gestation, the
greater the likelihood of perinatal mortality and morbidity.
Preterm birth remains the leading cause of neonatal mortal-
ity and morbidity [20].
The causes of preterm labor are still not known, and the
relative effectiveness and safety of the various therapies are
Abbreviations: d-Igl, d-indanylglycine; MeOAtc, 6-methoxy-2-
aminotetraline-2-carboxylic acid, Pff, d- and l-pentafluorophenylalanine;
Dmf, 2,4-dimethylphenylalanine; Tmf, 2,4,6,-trimethylphenylalanine; l-
and d-MeTcc, 1,2,3,4-tetrahydro-1-methyl--carboline-3-carboxylic acid;
Meb, p-methylbenzyl; Mpa, -mercaptopropionic acid; Mca, -mercapto-
,-cyclopentamethylenepropionic acid; Pen, ′-dimethylcysteine; Tos,
tosyl; Boc, N-tert-butyloxycarbonyl; pMBHA, p-methylbenzhydrylamine;
DCC, N,N′-dicyclohexylcarbodiimide; HPLC, high-performance liquid
chromatography; PMSF, phenylmethylsulfonyl fluoride
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unclear. The major form of treatment currently applied in
cases of preterm labor is the administration of selective
2-adrenergic agonists that inhibit myometrial contractility
by activation of the receptor-mediated adenylcyclase cas-
cade. Unfortunately, the use of these agents is associated
with significant maternal and fetal side-effects [2,21]. Al-
though other compounds have also been utilized for tocol-
ysis, questions remain as concerns their efficacy and safety.
It is evident that an effective tocolytic agent that has few or
no side-effects would be extremely valuable.
Although the causes of preterm labor are multifactorial,
it is becoming increasingly apparent that oxytocin (OT) has
an important role in preterm labor. It is accepted that both
OT itself and the sensitivity of the uterus to OT play crucial
roles in the initiation of both normal and pathologically early
deliveries [3,19]. The uterus contains OT and vasopressin
(VP) receptors. VP likewise stimulates uterine contractions,
but it is not known whether the uterotonic action of VP
is mediated by the VP1a receptor alone or also by the OT
receptor (OTR).
Blockade of the uterine OTR is one of the logical ap-
proaches to the prevention of preterm labor. Over the
past decade, a number of potent OTR antagonists have
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been developed and studied in animal models, AtosibanR
([1-deamino-d-Tyr(OEt)2-Thr4Orn8]OT), is the first OT
antagonist to be licensed for the treatment of preterm labor
[5].
This study reports on the synthesis and in vitro and in vivo
pharmacological investigations of new OT antagonists with
the general structure [Mpa1Xxx2Sar7Arg8]OT, substituted
at position 2 with conformationally constrained and bulky
amino acids.
2. Materials and methods
2.1. Animals
Animal investigations were carried out with the approval
of the Ethical Committee for Animal Research, Univer-
sity of Szeged (registration number 23/1999), in accordance
with the Guiding Principles for the Care and Use of Re-
search Animals. Sexually mature female Sprague–Dawley
rats (body mass: 200–300 g) and Charles Liver guinea-pigs
were used in the experiments. Mating with males was car-
ried out in the early morning hours. Copulation was justi-
fied by the presence of a copulation plug or spermatozoa
in the vagina. The day of conception was considered to be
the first day of pregnancy. Animals were housed in tem-
perature and humidity-controlled, light-regulated (12 h of
light, 12 h of dark) rooms, with water and food intake ad
libitum.
2.2. Peptide synthesis
The syntheses of these peptides were earlier described
in Letters in Peptide Synthesis [1]. Briefly, the peptides
were synthesized by a solid-phase peptide technique, uti-
lizing Boc chemistry. Side-chain protecting groups were
as follows: Arg(Tos), Cys(Meb) and Mpa(Meb). The pep-
tide chains were elongated on p-methylbenzhydrylamine
(pMBHA) resin (0.31–1.1 mmol/g). Couplings were per-
formed with DCC, with the exceptions of Asn, Gln and Arg,
which were incorporated as their 1-hydroxybenzotriazole
esters. Amino acid incorporation was monitored via the nin-
hydrin test. The completed peptide resins were treated with
liquid HF/dimethyl sulfide/p-cresol/anisole/p-thiocresol
(93:4:1:1:1, v/v) at 0 ◦C for 1 h. The HF was removed and
the resulting free peptides were solubilized in 10% aqueous
acetic acid (1 mg/10 ml) and folded by stirring with 0.01 M
potassium hexacyanoferrate(III). The completion of disul-
fide formation was monitored by means of HPLC. After it
was complete, the solution was lyophilized.
The crude peptides were purified by reverse-phase HPLC
(RP-HPLC) on a Lichrosorb RP-18 10 column (16 mm ×
250 mm). The purity was checked by RP-HPLC. The prod-
ucts proved to be substantially pure (>95%).
The structures of the new analogs were proved by mass
spectrometry.
2.3. Membrane preparation
The affinities and the selectivities of the synthesized pep-
tides for the OTR and VP receptors (VPR) were determined
by radioligand binding assay.
The OTR binding assays were carried out on a uterine
plasma membrane fraction of term pregnant guinea-pig
uterus. The plasma membrane was prepared by a modi-
fication of the previously described method [4]. Uterine
tissue was minced and homogenized in 10 vol. ice-cold
buffer containing 10 mM Tris–HCl, 1.5 mM EDTA, 0.5 mM
dithiotreitol and 1 mM phenylmethylsulphonyl fluoride
(PMSF); pH 7.5. After homogenization with an Ultra Turrax
homogenizer, the suspension was centrifuged at 1000 × g
for 10 min at 4 ◦C. The resultant supernatant was cen-
trifuged at 100 000× g for 60 min at 4 ◦C. The pellets were
washed and resuspended for storage in Ca2+-free Hanks’
salt solution with 1 mM PMSF at a protein concentration
of approximately 10 mg/ml at −70 ◦C.
Rat kidney inner medulla containing VP2 receptors and
rat liver plasma containing VP1 receptors were prepared
by the following method [14]. Adult male Sprague–Dawley
rats (200–300 g) were killed by stunning and decapitation.
The medullopapillary region of the kidneys and the livers
were homogenized with an Ultra Turrax in 20 vol. ice-cold
buffer containing 10 mM Tris–HCl and 0.1 mM PMSF; pH
7.4. The homogenate was centrifuged at 500 × g for 5 min
to remove all debris and nuclei. The supernatant was cen-
trifuged at 20 000 × g for 20 min, and the pellet was re-
suspended in ice-cold incubation buffer containing 100 mM
Tris–HCl (pH 7.4), 10 mM MgCl2, 0.5 mg/ml bacitracin and
100 IU/ml aprotinin, and recentrifuged at 20 000×g. The fi-
nal pellet was resuspended for storage in 10 vol. incubation
buffer.
2.4. Receptor assays
The affinities of OT and its analogs for the OTR and VPRs
were determined by heterolog displacement analyses. In the
OTR assay, the assay buffer consisted of 25 mM Tris–HCl,
1 mM MnCl2, 1 mM PMSF and 0.1% BSA; pH 7.5. The
affinities of the OT analogs were investigated in the presence
of 1 nM [3H]oxytocin (44 Ci/mmol) at 22 ◦C for 60 min.
In the VPR assay, the assay buffer contained 100 mM
Tris–HCl, 10 mM MgCl2, 0.5 mg/ml bacitracin, 100 IU/ml
aprotinin and 0.1% BSA. The competition binding assays
were carried out in the presence of 1 nM [3H]vasopressin
(75 Ci/mmol) at 25 ◦C for 120 min. In both cases, the non-
specific binding was determined in the presence of 10−5 M
unlabeled OT and VP. The bound ligand was separated
from the free ligand by rapid filtration through a Whatman
GF/C glass fiber filter, using a Brandel M24R cell harvester.
Specific binding was determined by subtracting the nonspe-
cific binding from the total binding. All assays were carried
out at least three times in duplicate and values were given
as means ± S.E.M. Binding parameters were calculated
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with the Prism 2.01 (GraphPad Software, USA) computer
program.
2.5. Measurement of uterine contraction in vitro
Uteri were removed from 60 to 65-day pregnant
guinea-pigs, and trimmed of fat, the feto-placental units were
removed and the decidua was scraped off. A uterine muscle
strip (10 mm long and 10 mm wide) was suspended verti-
cally in a 10 ml organ bath containing Van Dyke-Hastings
solution [8]. The bath temperature was maintained at 37 ◦C
and O2:CO2 (95%:5%) was bubbled through the solution.
The initial tension was set at 1.0 g.
The uterine strips were equilibrated for 60 min before the
onset of the experiments and allowed to contract sponta-
neously and display stable rhythmic contractions. At the end
of the adaptation period, the antagonists were added to the
tissue bath. After a 30 min incubation in the presence of the
antagonist, increasing doses ranging from 10−9 to 10−3 M
OT were administered. The contractions were measured with
a strain gauge transducer (SG-02, Experimetria UK Ltd.)
and recorded by an ISOSYS Data Acquisition System (Ex-
perimetria UK Ltd.). The contractile response to OT was
measured as the area under the curve during a 3 min period.
Areas under curves were evaluated with the computer pro-
gram as mentioned above. For statistical evaluations, data
were analyzed by means of the ANOVA; post hoc compar-
isons were performed with the Newman–Keuls test.
2.6. Measurement of uterine contraction in vivo
Twenty-four hours after spontaneous delivery, female
Sprague–Dawley rats were anesthetized with urethane
(1 g/kg, i.p.). After cannulation of the jugular vein, a Millar
Fig. 1. Amino acids incorporated at position 2.
catheter (Millar Instruments Inc., Houston, TX, USA) fitted
with a liquid-filled latex microballoon was inserted into the
uterine horn through a small section above the cervical part.
At the end of the 30 min equilibration period, the intrauterine
pressure was recorded and the effects of the intravenously
administered compounds were assessed by expressing the
integrated tension relating to a 5 min period after the ad-
ministration of each dose as a percentage of the average
for three 5 min periods before the first administration. The
maximum inhibition and the ED50 values were calculated.
Statistical analysis was carried out as mentioned above.
3. Results
3.1. Receptor binding
The synthesized OT antagonists contained different cyclic
-amino acids at position 2: d-indanylglycine (d-Igl),
6-methoxy-2-aminotetraline-2-carboxylic acid (MeOAtc),
d- and l-pentafluorophenylalanine (Pff), 2,4-dimethyl-
phenylalanine (Dmf), 2,4,6,-trimethylphenylalanine (Tmf),
and conformationally constrained derivatives of tryptophan:
1,2,3,4-tetrahydro-1-methyl--carboline-3-carboxylic acid
(l- and d-MeTcc) (Fig. 1).
OT was found to bind to the guinea-pig uterine OTR with
a dissociation constant of 2.51±0.6 nM. The inhibition con-
stants (Ki) of the tested OT antagonists relative to the OT,
VP1 and VP2 receptors are listed in Table 1. For compari-
son, atosiban was tested in the same system. Each drug dis-
placed the tritiated OT binding in a concentration-dependent
manner.
The Ki values of three newly synthesized analogs for
the OTR were similar to that of atosiban. Substitution at
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Table 1
Ki values of the tested peptides for the OT, VP1 and VP2 receptors
OT antagonists Ki values (nM ± S.E.M.)
OTR VP1 receptor VP2 receptor
Atosiban 5.76 ± 1.48 1412 ± 145 667 ± 163
[Mpa1, Dmf2, Sar7, Arg8]OTa 1.49 ± 0.31 48.4 ± 25.7 70.8 ± 15.8
[Mpa1, d-Igl2, Sar7, Arg8]OT 3.81 ± 0.18 263 ± 36.9 425 ± 29.1
[Mpa1, Tmf2, Sar7, Arg8]OTa 46.5 ± 19.6 254 ± 128 384 ± 99.3
[Mpa1, d-Pff2, Sar7, Arg8]OT 52.9 ± 20.5 5420 ± 2490 2250 ± 820
[Mpa1, MeOAtc2, Sar7, Arg8]OTa 56.2 ± 9.56 1940 ± 1230 1640 ± 1100
[Mpa1, l-Pff2, Sar7, Arg8]OT 230 ± 83.9 3420 ± 620 9950 ± 2470
[Mpa1, l-MeTcc2, Sar7, Arg8]OT 2020 ± 124 3740 ± 2850 5400 ± 590
[Mpa1, d-MeTcc2, Sar7, Arg8]OT 4700 ±745 9564 ± 3412 55100 ± 6200
a The absolute configuration has not been determined.
position 2 with Dmf and d-Igl resulted in the compounds
with the highest affinities.Incorporation of a further methyl
group at position 6 of the phenylalanine ring (Tmf) decreased
the affinity for the OTR.
As concerns Pff, the incorporation of the two configura-
tions of the amino acids resulted in analogs with different
affinities.
Substitution with the two configurations of the-carboline
derivatives led to the lowest affinities for the OTR.
Table 2 gives the selectivity ratios of the newly synthe-
sized OT antagonists. The selectivity ratios were calculated
from the Ki values for the OTR and the different types of
VPRs.
None of the tested analogs had such a high selectivity as
atosiban. However, five of them exhibited relatively good
selectivities: [Mpa1, d-Pff2, Sar7, Arg8]OT, [Mpa1, d-Igl2,
Sar7, Arg8]OT, [Mpa1, MeoAtc2, Sar7, Arg8]OT, [Mpa1,
Dmf2, Sar7, Arg8]OT and [Mpa1, l-Pff2, Sar7, Arg8]OT.
This means that these compounds have affinities higher by
two orders for the OTR than for the VPRs. [Mpa1, Tmf2,
Sar7, Arg8]OT, [Mpa1, d-MeTcc2, Sar7, Arg8]OT and
[Mpa1, l-MeTcc2, Sar7, Arg8]OT had weaker selectivities
for the OTRs. With the exception of l-MeTcc, none of the
Table 2
Selectivity ratios of the tested peptides
OT antagonists Selectivity ratio
OT/VP1 OT/VP2
Atosiban 0.004 0.008
[Mpa1, d-Pff2, Sar7, Arg8]OT 0.010 0.023
[Mpa1, d-Igl2, Sar7, Arg8]OT 0.014 0.009
[Mpa1, MeOAtc2, Sar7, Arg8]Ota 0.029 0.034
[Mpa1, Dmf2, Sar7, Arg8]Ota 0.031 0.021
[Mpa1, l-Pff2, Sar7, Arg8]OT 0.067 0.023
[Mpa1, Tmf2, Sar7, Arg8]Ota 0.183 0.121
[Mpa1, d-MeTcc2, Sar7, Arg8]OT 0.491 0.085
[Mpa1, l-MeTcc2, Sar7, Arg8]OT 0.540 0.374
a The absolute configuration has not been determined.
tested OT antagonists could differentiate between the two
types of VPR.
3.2. In vitro uterine contractility studies
An initial series of studies was undertaken to determine
the effects of the tested peptides on OT-induced contrac-
tions in isolated strips of pregnant guinea-pig uterus. OT
induced dose-related increases in basal tone, amplitude and
frequency of contraction, with maximum effects. In the pres-
ence of the newly synthesized OT antagonists, the maximum
effects were significantly decreased, F(9, 72) = 5.276, P <
0.0001 (Figs. 2 and 3).
In contrast, in the presence of atosiban, a higher concen-
tration of OT was required to elicit the same degree of my-
ometrial contractility. In isolated guinea-pig uterine strips,
atosiban (10−8 M) displaced the OT dose–response curve to
the right in a parallel fashion, without significant change in
the maximum effect (Fig. 4).
3.3. Uterine contractility in vivo
The aim of the next series of experiments was to examine
the ability of four newly synthesized OT antagonists to in-
hibit the spontaneous contractility in the 24 h postpartum rat
uterus. Four compounds were selected on the basis of their
good in vitro effectivities and were tested in an in vivo sys-
tem. The OT antagonists were administered intravenously,
in a cumulative manner (the first dose was 0.001 mg/kg).
All the tested peptides markedly suppressed the myometrial
contraction in a dose-dependent way (Fig. 5).
The calculated maximum inhibition of the spontaneous
uterine motility and ED50 values are listed in Table 3. For
comparison, atosiban was tested in the same system.
These data demonstrate that all of the tested peptides are
effective in inhibiting the spontaneous contractility of the
rat uterus in vivo. The antioxytocic activity of the peptide
substituted with Dmf at position 2 is comparable to that
of atosiban. Incorporation of the other amino acids resulted
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Fig. 2. The dose–response curves represent the effects of OT on isolated guinea-pig uterus alone and in the presence of the newly synthesized OT
antagonists. The spontaneous uterine contractility was taken as 100%. All of the tested peptides significantly decreased the maximum effect observed
with OT, without any significant change in the ED50 value. (Values are given as means± S.E.M.).
Fig. 3. Statistical comparison of the antioxytocic effects of the tested
peptides. Each bar represents the maximum effects of OT alone and in the
presence of the tested peptides in the isolated pregnant guinea-pig uterus
(results of Newman–Keuls post hoc test, ns: not significant, *P < 0.05;
**P < 0.01; ***P < 0.001).
Fig. 4. The dose–response curves represent the effect of OT alone and in
the presence of atosiban. The spontaneous uterine contractility was taken
as 100%. Atosiban did not decrease the maximum effect of OT, but sig-
nificantly changed the ED50 of OT. (Values are given as means±S.E.M.).
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Fig. 5. The dose–response curves represent the inhibitory effects of
the tested peptides on the postpartum rat in vivo. The tested peptides
were given intravenously, in a cumulative way. (The data are the aver-
ages of the results of six independent experiments; values are given as
means± S.E.M.).
Table 3
Calculated maximum inhibition and ED50 values of the tested peptides
OT antagonists Maximal effect (%) ED50 (g/kg)
Atosiban 50.23 5.568
[Mpa1, d-Pff2, Sar7, Arg8]OT 35.22 8.293
[Mpa1, d-Igl2, Sar7, Arg8]OT 38.04 6.276
[Mpa1, Dmf2, Sar7, Arg8]OT 45.57 5.330
[Mpa1, Tmf2, Sar7, Arg8]OT 36.18 6.449
in analogs with moderate activities. There were no marked
differences in the ED50 values.
4. Discussion
Although the role of OT in the spontaneous onset of labor
remains controversial, it may be concluded that OT antago-
nists offer a potentially useful approach for the management
or even the prevention of uncomplicated preterm labor. The
primary attraction is their apparent myometrial selectivity
and the lack of side-effects as compared with other available
therapies, e.g. -mimetics. A number of studies have dealt
with the design and pharmacological investigation of new
OT antagonists. During the development of the OT antago-
nists, modification of the OT molecule at positions 1, 2, 4 or
7 and 8 produced analogs with higher receptor affinities for
the myometrium in vitro [6,7,10,15,16]. The most potent of
these was atosiban, which subsequently underwent clinical
evaluation.
These synthesized peptides are 1-deamino-7-sarcosine-8-
arginine analogs. It was observed in previous studies [22]
that appropriate modification of the Tyr at position 2 plays a
crucial role in determining the antagonistic property. Our ap-
proaches in the design of more effective OT antagonists are
based mainly on the incorporation of bulky apolar side-chain
amino acids with a conformationally constrained restricted
feature at position 2 [9,11–13]. These small peptides are
rather flexible molecules, and their three-dimensional struc-
ture depends highly on the environment in solution. We at-
tempted to restrict this relatively extensive conformational
freedom in order to stabilize the bioactive antioxytocic con-
formation. Such conformational restriction can be achieved
by incorporating a second intramolecular ring or a sub-
stituent involving a constrained amino acid [18].
The results of receptor analyses indicate that the OT an-
tagonists containing phenylalanine derivatives at position 2
have higher affinities for the OTR than those containing tryp-
tophan analogs. It is conceivable that the incorporation of a
tryptophan analogue into the peptide results in a molecule
that is too large and rigid to bind to the apolar side-chain
binding pocket of the OTR. In order to achieve better affinity,
different phenylalanine derivatives were synthesized for in-
corporation. Of these compounds, Dmf and d-Igl resulted in
the compounds with the highest affinities, similar to that of
atosiban. Incorporation of a further methyl group into posi-
tion 6 of the phenylalanine ring (Tmf) decreased the affinity
for the OTR and destroyed the selectivity too. Substitution
of the phenylalanine ring with halogen atoms decreased the
affinity for the OTR. The binding to the OTR of the d isomer
of this phenyalanine derivative is higher than in the case of
the l isomer. The 6-methoxy-2-aminotetraline-2-carboxylic
acid derivative was designed by modification of a previ-
ously synthesized and investigated OT antagonist containing
aminotetralinecarboxylic acid at position 2. The new OT
antagonist, [Mpa1, MeOAtc2, Sar7, Arg8]OT, has higher
affinity and selectivity than those of the original molecule.
The presence of the methoxy at position 6 of the tetraline
ring improves the interaction of the analog and the OTR.
The rationale for the development of OT antagonists was
based on producing a novel compound that mimicked nor-
mal physiological processes with high uterine specificity,
but with limited or no systemic effects. The specificity for
the OTR in the uterus is the key to the clinical applica-
tion of the OT antagonists, since the major problem with
all current tocolytic agents is their systemic activity, which
causes potentially harmful multiorgan side-effects. All of
the newly synthesized OT antagonists exhibit OTR selectiv-
ity, but lower than that of atosiban. Incorporation of d-Igl
and d-Pff at position 2 resulted in the most selective com-
pounds. The analogs containing an amino acid with the l
or d configuration at position 2 proved to be less selective
than their diastereomers, so the l or d configuration at this
site is unfavorable for good selectivity.
The results of the in vitro contractility study indicated that
all the tested peptides were noncompetitive antagonists, in
contrast with atosiban, which is a competitive one [17]. This
pharmacological characteristic can not be explained by the
chemical features of these peptides. Washing experiments
demonstrated that none of the synthesized OT antagonists
can produce an irreversible interaction to the binding sites of
the OTR and VPRs. Pregnant guinea-pig uterine membrane
was preincubated in the presence of the tested peptides
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for 30 min at 37 ◦C, and the specific binding was then
measured as described in Section 2. The remainder of the
preincubated membrane fraction was diluted to a 15-fold
volume and centrifuged, and the specific binding was mea-
sured again. This dilution–centrifugation–binding proce-
dure was performed three times. There was no significant
decrease in the specific binding sites. Consequently, this
noncompetitive antagonism is due to the size and structure
of the apolar side-chain of the amino acid at position 2. In
the new peptides, the amino acids at this position are more
conformationally constrained than that in atosiban, which
can explain their behavior.
The results of the in vivo experiments support the phar-
macological antagonistic nature of these peptides. All of the
tested peptides inhibited the intrinsic OT-induced contrac-
tion in a dose-dependent manner. The incorporation of Dmf
resulted in the most effective OT antagonist among the tested
peptides. This may be due to the size and the arrangement of
the side-chain of the amino acids at position 2. The pheny-
lalanine ring substituted at positions 2 and 4 with methyl
groups is needed for strong antioxytocic activity.
As regards these syntheses of OT antagonists, the incor-
poration of Dmf at position 2 resulted in a peptide that was
nearly equipotent to atosiban. These two compounds have
similar affinities for the OTR and inhibitory effects in the in
vivo system. However, atosiban has a better selectivity for
the OTR.
In consequence of their pseudoirreversible pharmacolog-
ical properties, these peptides comprise a novel group of
OT antagonists for potential clinical use. This noncompet-
itive pharmacological nature may be of therapeutic benefit
because of the sustained effect on the myometrium. In the
near future, a well-tolerated, effective, specific and ratio-
nally designed tocolytic agent may change the procedure
of tocolysis. The noncompetitive OT antagonists may be
among such promising drug novelties.
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